Taipei-headquartered cancer therapy developer ACT Genomics Co., Ltd (ACTG) announced on Monday that it has completed an undisclosed equity financing from US Aflac Inc’s investment arm Aflac Ventures LLC, Kyoto University, Innovation Capital, and other strategic investors.
Continue reading with Data Vantage
Venture-backed company data in SE Asia, India, Pakistan, Bangladesh.
Instant investment updates and valuations.
Tailored search, 3 monthly reports.
Industry-trusted platform.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
